A Randomized, Placebo-Controlled, Dose-Response Trial of Venlafaxine Hydrochloride in the Treatment of Major Depression

Rudolph, Richard L.; Fabre, Louis F.; Feighner, John P.; Rickels, Karl; Entsuah, Richard; Derivan, Albert T.

doi:10.4088/jcp.v59n0305

Cited by 122 publications

(62 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was no report of insomnia during venlafaxine treatment. Anorexia and weight loss have also been reported during venlafaxine treatment (Rudolph et al, 1998;Kraus et al, 2002). In this study, there were no reports of reduced appetite or anorexia during venlafaxine treatment.…”

Section: Discussionmentioning

confidence: 40%

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double‐blind, randomised 6‐month comparative trial with citalopram

Allard

Gram

Timdahl³

et al. 2004

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 40%

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double‐blind, randomised 6‐month comparative trial with citalopram

Allard

Gram

Timdahl³

et al. 2004

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…A fixed dose-response study with sertraline failed to find a dose-response relationship with doses from 50 mg/day to 200 mg/day [Sheikh et al, 2000], whereas a fixeddose study with paroxetine reported significant separation from placebo at 40 mg/day but not at 20 mg/day [Ballenger et al, 1998b]. Venlafaxine has demonstrated a positive dose-response relationship for the treatment of major depression [Kelsey, 1996;Khan et al, 1998;Rudolph et al, 1998], and it is possible that such a response would also be observed among patients with panic and comorbid major depression treated with venlafaxine ER. However, this issue cannot be addressed in this study, which excluded patients with significant depression.…”

Section: Discussionmentioning

confidence: 99%

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder

Pollack¹,

Lepola²,

Koponen³

et al. 2006

Depress. Anxiety

View full text Add to dashboard Cite

To date, no large-scale, controlled trial comparing a serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor with placebo for the treatment of panic disorder has been reported. This double-blind study compares the efficacy of venlafaxine extended-release (ER) and paroxetine with placebo. A total of 664 nondepressed adult outpatients who met DSM-IV criteria for panic disorder (with or without agoraphobia) were randomly assigned to 12 weeks of treatment with placebo or fixed-dose venlafaxine ER (75 mg/day or 150 mg/ day), or paroxetine 40 mg/day. The primary measure was the percentage of patients free from full-symptom panic attacks, assessed with the Panic and Anticipatory Anxiety Scale (PAAS). Secondary measures included the Panic Disorder Severity Scale, Clinical Global Impressions-Severity (CGI-S) andImprovement (CGI-I) scales; response (CGI-I rating of very much improved or much improved), remission (CGI-S rating of not at all ill or borderline ill and no PAAS full-symptom panic attacks); and measures of depression, anxiety, phobic fear and avoidance, anticipatory anxiety, functioning, and quality of life. Intent-to-treat, last observation carried forward analysis showed that mean improvement on most measures was greater with venlafaxine ER or paroxetine than with placebo. No significant differences were observed between active treatment groups. Panic-free rates at end point with active treatment ranged from 54% to 61%, compared with 35% for placebo. Approximately 75% of patients given active treatment were responders, and nearly 45% achieved remission. The placebo response rate was slightly above 55%, with remission near 25%. Adverse events were mild or moderate and similar between active treatment groups. Venlafaxine ER and paroxetine were effective and well tolerated in the treatment of panic disorder.

show abstract

“…4 Clinically, venlafaxine hydrochloride, 375 mg/d led to a more rapid onset of antidepressant efficacy than did 75 mg/d. 5 Furthermore, venlafaxine has an ascending dose-antidepressant response curve 6 inconsistent with a single, saturable mechanism of action. Finally, the adverse effect profile of venlafaxine hydrochloride at 75 mg/d is typical of an SSRI (nausea, vomiting, gastrointestinal disturbances, and sexual dysfunction), but at higher doses, patients also experience effects similar to those of an NE uptake inhibitor (increased sweating, dry mouth, increased heart rate, and increased blood pressure).…”

mentioning

confidence: 99%

Evidence of the Dual Mechanisms of Action of Venlafaxine

Harvey¹,

Rudolph²,

Preskorn³

2000

Arch Gen Psychiatry

Self Cite

265

147

View full text Add to dashboard Cite

Background: Indirect evidence suggests that the antidepressant venlafaxine hydrochloride selectively inhibits serotonin (5-HT) uptake at low doses, whereas at high doses, it inhibits both 5-HT and norepinephrine (NE) uptake. We hypothesized that, in vivo, both high and low doses would inhibit the 5-HT uptake of platelets but that the higher dose would differentially blunt the pressor response to tyramine, a marker for NE uptake.

show abstract

A Randomized, Placebo-Controlled, Dose-Response Trial of Venlafaxine Hydrochloride in the Treatment of Major Depression

Cited by 122 publications

References 0 publications

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double‐blind, randomised 6‐month comparative trial with citalopram

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double‐blind, randomised 6‐month comparative trial with citalopram

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder

Evidence of the Dual Mechanisms of Action of Venlafaxine

Contact Info

Product

Resources

About